251 related articles for article (PubMed ID: 19109232)
1. Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
Margaritis P; Roy E; Aljamali MN; Downey HD; Giger U; Zhou S; Merricks E; Dillow A; Ezban M; Nichols TC; High KA
Blood; 2009 Apr; 113(16):3682-9. PubMed ID: 19109232
[TBL] [Abstract][Full Text] [Related]
2. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
3. Gene-based continuous expression of FVIIa for the treatment of hemophilia.
Margaritis P
Front Biosci (Schol Ed); 2012 Jan; 4(1):287-99. PubMed ID: 22202061
[TBL] [Abstract][Full Text] [Related]
4. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.
Margaritis P; Arruda VR; Aljamali M; Camire RM; Schlachterman A; High KA
J Clin Invest; 2004 Apr; 113(7):1025-31. PubMed ID: 15057309
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of factor VII ameliorates bleeding diathesis of factor VIII-deficient mice with inhibitors.
Yasumoto A; Madoiwa S; Kashiwakura Y; Ishiwata A; Ohmori T; Mizukami H; Ozawa K; Sakata Y; Mimuro J
Thromb Res; 2013 May; 131(5):444-9. PubMed ID: 23566532
[TBL] [Abstract][Full Text] [Related]
7. Long-term expression of canine FVIIa in hemophilic dogs.
Margaritis P
Thromb Res; 2010 Apr; 125 Suppl 1(Suppl 1):S60-2. PubMed ID: 20149416
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for the hemophilias.
VandenDriessche T; Collen D; Chuah MK
J Thromb Haemost; 2003 Jul; 1(7):1550-8. PubMed ID: 12871290
[TBL] [Abstract][Full Text] [Related]
10. Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.
Zintner SM; Small JC; Pavani G; Dankner L; Marcos-Contreras OA; Gimotty PA; Kjelgaard-Hansen M; Wiinberg B; Margaritis P
Blood Adv; 2019 Feb; 3(3):301-311. PubMed ID: 30705032
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
12. Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility.
Knudsen T; Kristensen AT; Sørensen BB; Olsen OH; Stennicke HR; Petersen LC
J Thromb Haemost; 2010 Aug; 8(8):1763-72. PubMed ID: 20524980
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
14. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
Margaritis P; Roy E; Faella A; Downey HD; Ivanciu L; Pavani G; Zhou S; Bunte RM; High KA
Blood; 2011 Apr; 117(15):3974-82. PubMed ID: 21325603
[TBL] [Abstract][Full Text] [Related]
15. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
16. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
[TBL] [Abstract][Full Text] [Related]
17. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
[TBL] [Abstract][Full Text] [Related]
19. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
[TBL] [Abstract][Full Text] [Related]
20. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.
McCORMACK WM; Seiler MP; Bertin TK; Ubhayakar K; Palmer DJ; Ng P; Nichols TC; Lee B
J Thromb Haemost; 2006 Jun; 4(6):1218-1225. PubMed ID: 16706963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
